


**Supplemental Figure 1 Cytotoxic effect of Doxorubicin or Doxorubicin combined with GC7 in OSCC cells transfected with eukaryotic initiation factor 5A-2 (eIF5A-2) siRNA.**

Silencing of eIF5A-2 by siRNA-transfection inhibited the synergistic cytotoxic effect of Doxorubicin combined with GC7 in Cal27 (A), Tca8113 (B), and HN30 (C) cells. The best fit lines (solid) and 95% confidence intervals (dashed) are indicated for the treatments in different cells.  $p > 0.05$  for Doxorubicin+GC7 vs. Doxorubicin.



**Supplemental Table 1 IC<sub>50</sub> values of Doxorubicin in Twist-1 siRNA transfected OSCC cell lines with or without GC7 treatment**

Cell lines	IC <sub>50</sub> (µg/mL)	
	Doxorubicin	Doxorubicin+GC7
Cal27	0.519±0.027	0.455±0.021*
HN30	0.143±0.011	0.180±0.011*
Tca8113	0.531±0.029	0.518±0.032*

Mean ± SD, \*P>0.05 for Doxorubicin+GC7 vs. Doxorubicin

**Supplemental Table 2 IC<sub>50</sub> values of Doxorubicin in Eukaryotic initiation factor 5A2 (eIF5A2) siRNA transfected OSCC cell lines with or without GC7 treatment**

Cell lines	IC <sub>50</sub> (µg/mL)	
	Doxorubicin	Doxorubicin+GC7
Cal27	0.435±0.017	0.474±0.023*
HN30	0.423±0.016	0.382±0.015*
Tca8113	0.934±0.097	0.663±0.017*

Mean ± SD, \*P>0.05 for Doxorubicin+GC7 vs. Doxorubicin